Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tore Saxne

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Nature Reviews. Rheumatology|December 2, 2010
The role of the cartilage matrix in osteoarthritisDick Heinegård, Tore Saxne
Arthritis and Rheumatism|February 1, 2006
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern SwedenLars Erik Kristensen, Tore Saxne, Pierre Geborek
The Journal of Rheumatology|March 3, 2005
Prediction of mortality in rheumatoid arthritis based on disease activity markersChristina Book, Tore Saxne, Lennart T H Jacobsson
BMC Musculoskeletal Disorders|April 25, 2009
Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agentsAnders Gülfe, Daniel Aletaha, Tore Saxne, et al.
Arthritis Research & Therapy|January 5, 2013
Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugsMeliha Crnkic Kapetanovic, Tore Saxne, Lennart Truedsson, et al.
BMC Rheumatology|December 1, 2023
Cardiovascular disease risk in early rheumatoid arthritis: the impact of cartilage oligomeric matrix protein (COMP) and disease activityEmil Rydell, Lennart Th Jacobsson, Tore Saxne, et al.
Immunobiology|September 12, 2012
Interactions of the complement system with molecules of extracellular matrix: relevance for joint diseasesKaisa E Happonen, Dick Heinegård, Tore Saxne, et al.
The Journal of Rheumatology|February 17, 2015
Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort StudyJon Thorkell Einarsson, Pierre Geborek, Tore Saxne, et al.
Arthritis Research & Therapy|November 24, 2006
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenLars Erik Kristensen, Tore Saxne, Jan-Ake Nilsson, et al.
Osteoarthritis and Cartilage|January 16, 2004
Fibronectin fragments cause release and degradation of collagen-binding molecules from equine explant culturesAnna Johnson, Roger Smith, Tore Saxne, et al.
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Nature Reviews. Rheumatology|December 2, 2010
The role of the cartilage matrix in osteoarthritisDick Heinegård, Tore Saxne
Arthritis and Rheumatism|February 1, 2006
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern SwedenLars Erik Kristensen, Tore Saxne, Pierre Geborek
The Journal of Rheumatology|March 3, 2005
Prediction of mortality in rheumatoid arthritis based on disease activity markersChristina Book, Tore Saxne, Lennart T H Jacobsson
BMC Musculoskeletal Disorders|April 25, 2009
Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agentsAnders Gülfe, Daniel Aletaha, Tore Saxne, et al.
Arthritis Research & Therapy|January 5, 2013
Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugsMeliha Crnkic Kapetanovic, Tore Saxne, Lennart Truedsson, et al.
BMC Rheumatology|December 1, 2023
Cardiovascular disease risk in early rheumatoid arthritis: the impact of cartilage oligomeric matrix protein (COMP) and disease activityEmil Rydell, Lennart Th Jacobsson, Tore Saxne, et al.
Immunobiology|September 12, 2012
Interactions of the complement system with molecules of extracellular matrix: relevance for joint diseasesKaisa E Happonen, Dick Heinegård, Tore Saxne, et al.
The Journal of Rheumatology|February 17, 2015
Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort StudyJon Thorkell Einarsson, Pierre Geborek, Tore Saxne, et al.
Arthritis Research & Therapy|November 24, 2006
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenLars Erik Kristensen, Tore Saxne, Jan-Ake Nilsson, et al.
Osteoarthritis and Cartilage|January 16, 2004
Fibronectin fragments cause release and degradation of collagen-binding molecules from equine explant culturesAnna Johnson, Roger Smith, Tore Saxne, et al.
Pageof 9